Starting Treatment with Agonist Replacement Therapies (START) Study

This is Archived Content. This content is available for historical purposes only. It may not reflect the current state of science or language from the National Institute on Drug Abuse (NIDA). View current information on nida.nih.gov.

The CTN collaborated with the Division of Pharmacotherapies & Medical Consequences of Drug Abuse (DPMCDA) on this multi-centered trial to compare the effect of buprenorphine/naloxone (Bup/Nx) and methadone (MET) on liver function. This was a randomized, open-label, multi-center, Phase 4 study in participants entering opioid agonist treatment programs at community centers (methadone centers) throughout the country. The study randomized approximately 1,300 participants at 8 sites across 6 Nodes.

CTN Protocol ID: 
CTN-0027
DSMB ID: 
DSMB-0027
ClinicalTrials.gov ID: 

Principal Investigator(s)

Walter Ling, M.D.
Director
Integrated Substance Abuse Programs
University of California, Los Angeles
11075 Santa Monica Boulevard
Suite 200
Los Angeles, CA 90025
lwalter@ucla.edu

Participating Sites